Search

Your search keyword '"Simon, Viviana"' showing total 715 results
Start Over Author "Simon, Viviana"
715 results on '"Simon, Viviana"'

1. IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition

Author

Ozonoff, Al, Ehrlich, Lauren IR, Melamed, Esther, Sesma, Ana Fernandez, Simon, Viviana, Pulendran, Bali, Nadeau, Kari C, Davis, Mark M, McCoey, Grace A, Sekaly, Rafick, Baden, Lindsey R, Levy, Ofer, Schaenman, Joanna, Reed, Elaine F, Shaw, Albert C, Hafler, David A, Montgomery, Ruth R, Kleinstein, Steven H, Becker, Patrice M, Augustine, Alison D, Calfee, Carolyn S, Erle, David J, DeBakey, Michael E, Corry, David B, Kheradmand, Farrah, Atkinson, Mark A, Brakenridge, Scott C, Higuita, Nelson I Agudelo, Metcalf, Jordan P, Hough, Catherine L, Messer, William B, Kraft, Monica, Bime, Chris, Peters, Bjoern, Milliren, Carly E, Syphurs, Caitlin, McEnaney, Kerry, Barton, Brenda, Lentucci, Claudia, Saluvan, Mehmet, Chang, Ana C, Hoch, Annmarie, Albert, Marisa, Shaheen, Tanzia, Kho, Alvin T, Liu, Shanshan, Thomas, Sanya, Chen, Jing, Murphy, Maimouna D, Cooney, Mitchell, Hayati, Arash Nemati, Bryant, Robert, Abraham, James, Jayavelu, Naresh Doni, Presnell, Scott, Jancsyk, Tomasz, Maguire, Cole, Qi, Jingjing, Lee, Brian, Fourati, Slim, Esserman, Denise A, Guan, Leying, Gygi, Jeremy, Pawar, Shrikant, Brito, Anderson, Fragiadakis, Gabriela K, Patel, Ravi, Overton, James A, Vita, Randi, Westendorf, Kerstin, Shannon, Casey P, Tebbutt, Scott J, Thyagarajan, Rama V, Rousseau, Justin F, Wylie, Dennis, Triplett, Todd A, Kojic, Erna, Chinthrajah, Sharon, Ahuja, Neera, Rogers, Angela J, Artandi, Maja, Geng, Linda, Yendewa, George, Powell, Debra L, Kim, James N, Simmons, Brent, Goonewardene, I Michael, Smith, Cecilia M, Martens, Mark, Sherman, Amy C, Walsh, Stephen R, Issa, Nicolas C, Salehi-Rad, Ramin, Dela Cruz, Charles, Farhadian, Shelli, Iwasaki, Akiko, Ko, Albert I, Anderson, Evan J, Mehta, Aneesh K, and Sevransky, Jonathan E

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Immunology, Infectious Diseases, Coronaviruses, Lung, Emerging Infectious Diseases, Inflammatory and immune system, Good Health and Well Being, Humans, COVID-19, Glycosylation, SARS-CoV-2, Glycosyltransferases, Complement System Proteins, Immunoglobulin M, IMPACC Network
Abstract

The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.

Published
2024

2. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.

Author

Aleman, Adolfo, van Kesteren, Morgan, Zajdman, Ariel, Srivastava, Komal, Cognigni, Christian, Mischka, Jacob, Chen, Lucia, Upadhyaya, Bhaskar, Serebryakova, Kseniya, Nardulli, Jessica, Lyttle, Neko, Kappes, Katerina, Jackson, Hayley, Gleason, Charles, Oostenink, Annika, Cai, Gianna, Van Oekelen, Oliver, van Bakel, Harm, Sordillo, Emilia, Cordon-Cardo, Carlos, Merad, Miriam, Jagannath, Sundar, Wajnberg, Ania, Simon, Viviana, and Parekh, Samir

Subjects
Bivalent vaccine, COVID-19, Hematological malignancy, Multiple Myeloma, Omicron, SARS-CoV-2, Humans, Multiple Myeloma, COVID-19 Vaccines, SARS-CoV-2, COVID-19, Immunoglobulin G, Immunity, Antibodies, Neutralizing, Antibodies, Viral, Vaccination
Abstract

BACKGROUND: The real-world impact of bivalent vaccines for wild type (WA.1) and Omicron variant (BA.5) is largely unknown in immunocompromised patients with Multiple Myeloma (MM). We characterize the humoral and cellular immune responses in patients with MM before and after receiving the bivalent booster, including neutralizing assays to identify patterns associated with continuing vulnerability to current variants (XBB1.16, EG5) in the current post-pandemic era. METHODS: We studied the humoral and cellular immune responses before and after bivalent booster immunization in 48 MM patients. Spike binding IgG antibody levels were measured by SARS-CoV-2 spike binding ELISA and neutralization capacity was assessed by a SARS-CoV-2 multi-cycle microneutralization assays to assess inhibition of live virus. We measured spike specific T-cell function using the QuantiFERON SARS-CoV-2 (Qiagen) assay as well as flow-cytometry based T-cell. In a subset of 38 patients, high-dimensional flow cytometry was performed to identify immune cell subsets associated with lack of humoral antibodies. FINDINGS: We find that bivalent vaccination provides significant boost in protection to the omicron variant in our MM patients, in a treatment specific manner. MM patients remain vulnerable to newer variants with mutations in the spike portion. Anti-CD38 and anti-BCMA therapies affect the immune machinery needed to produce antibodies. INTERPRETATION: Our study highlights varying immune responses observed in MM patients after receiving bivalent COVID-19 vaccination. Specifically, a subgroup of MM patients undergoing anti-CD38 and anti-BCMA therapy experience impairment in immune cells such DCs, B cells, NK cells and TFH cells, leading to an inability to generate adequate humoral and cellular responses to vaccination. FUNDING: National Cancer Institute (National Institutes of Health), National Institute of Allergy and Infectious Diseases (National Institutes of Health), NCI Serological Sciences Network for COVID-19 (SeroNet) and The Icahn School of Medicine at Mount Sinai.

Published
2023

4. Bat-borne H9N2 influenza virus evades MxA restriction and exhibits efficient replication and transmission in ferrets

Author

Halwe, Nico Joel, Hamberger, Lea, Sehl-Ewert, Julia, Mache, Christin, Schön, Jacob, Ulrich, Lorenz, Calvelage, Sten, Tönnies, Mario, Fuchs, Jonas, Bandawane, Pooja, Loganathan, Madhumathi, Abbad, Anass, Carreño, Juan Manuel, Bermúdez-González, Maria C., Simon, Viviana, Kandeil, Ahmed, El-Shesheny, Rabeh, Ali, Mohamed A., Kayali, Ghazi, Budt, Matthias, Hippenstiel, Stefan, Hocke, Andreas C., Krammer, Florian, Wolff, Thorsten, Schwemmle, Martin, Ciminski, Kevin, Hoffmann, Donata, and Beer, Martin

Published
2024
Full Text
View/download PDF

5. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study

Author

Ozonoff, Al, Jayavelu, Naresh Doni, Liu, Shanshan, Melamed, Esther, Milliren, Carly E., Qi, Jingjing, Geng, Linda N., McComsey, Grace A., Cairns, Charles B., Baden, Lindsey R., Schaenman, Joanna, Shaw, Albert C., Samaha, Hady, Seyfert-Margolis, Vicki, Krammer, Florian, Rosen, Lindsey B., Steen, Hanno, Syphurs, Caitlin, Dandekar, Ravi, Shannon, Casey P., Sekaly, Rafick P., Ehrlich, Lauren I. R., Corry, David B., Kheradmand, Farrah, Atkinson, Mark A., Brakenridge, Scott C., Higuita, Nelson I. Agudelo, Metcalf, Jordan P., Hough, Catherine L., Messer, William B., Pulendran, Bali, Nadeau, Kari C., Davis, Mark M., Sesma, Ana Fernandez, Simon, Viviana, van Bakel, Harm, Kim-Schulze, Seunghee, Hafler, David A., Levy, Ofer, Kraft, Monica, Bime, Chris, Haddad, Elias K., Calfee, Carolyn S., Erle, David J., Langelier, Charles R., Eckalbar, Walter, Bosinger, Steven E., Peters, Bjoern, Kleinstein, Steven H., Reed, Elaine F., Augustine, Alison D., Diray-Arce, Joann, Maecker, Holden T., Altman, Matthew C., Montgomery, Ruth R., Becker, Patrice M., and Rouphael, Nadine

Published
2024
Full Text
View/download PDF

6. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

Author

Ozonoff, Al, Schaenman, Joanna, Jayavelu, Naresh Doni, Milliren, Carly E, Calfee, Carolyn S, Cairns, Charles B, Kraft, Monica, Baden, Lindsey R, Shaw, Albert C, Krammer, Florian, van Bakel, Harm, Esserman, Denise A, Liu, Shanshan, Sesma, Ana Fernandez, Simon, Viviana, Hafler, David A, Montgomery, Ruth R, Kleinstein, Steven H, Levy, Ofer, Bime, Christian, Haddad, Elias K, Erle, David J, Pulendran, Bali, Nadeau, Kari C, Davis, Mark M, Hough, Catherine L, Messer, William B, Higuita, Nelson I Agudelo, Metcalf, Jordan P, Atkinson, Mark A, Brakenridge, Scott C, Corry, David, Kheradmand, Farrah, Ehrlich, Lauren IR, Melamed, Esther, McComsey, Grace A, Sekaly, Rafick, Diray-Arce, Joann, Peters, Bjoern, Augustine, Alison D, Reed, Elaine F, Altman, Matthew C, Becker, Patrice M, Rouphael, Nadine, Bime, Chris, McEnaney, Kerry, Barton, Brenda, Lentucci, Claudia, Saluvan, Mehmet, Chang, Ana C, Hoch, Annmarie, Albert, Marisa, Shaheen, Tanzia, Kho, Alvin T, Thomas, Sanya, Chen, Jing, Murphy, Maimouna D, Cooney, Mitchell, Presnell, Scott, and Fragiadakis, Gabriela K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Emerging Infectious Diseases, Lung, Genetics, Clinical Research, Coronaviruses, Prevention, Good Health and Well Being, COVID-19, Creatinine, Female, Hospitalization, Humans, Male, Phenotype, Prospective Studies, RNA, Viral, SARS-CoV-2, Severity of Illness Index, Troponin, Post-Acute COVID-19 Syndrome, Viral load, Antibody, IMPACC study group members, Public Health and Health Services, Clinical sciences, Epidemiology
Abstract

BackgroundBetter understanding of the association between characteristics of patients hospitalized with coronavirus disease 2019 (COVID-19) and outcome is needed to further improve upon patient management.MethodsImmunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective, observational study of 1164 patients from 20 hospitals across the United States. Disease severity was assessed using a 7-point ordinal scale based on degree of respiratory illness. Patients were prospectively surveyed for 1 year after discharge for post-acute sequalae of COVID-19 (PASC) through quarterly surveys. Demographics, comorbidities, radiographic findings, clinical laboratory values, SARS-CoV-2 PCR and serology were captured over a 28-day period. Multivariable logistic regression was performed.FindingsThe median age was 59 years (interquartile range [IQR] 20); 711 (61%) were men; overall mortality was 14%, and 228 (20%) required invasive mechanical ventilation. Unsupervised clustering of ordinal score over time revealed distinct disease course trajectories. Risk factors associated with prolonged hospitalization or death by day 28 included age ≥ 65 years (odds ratio [OR], 2.01; 95% CI 1.28-3.17), Hispanic ethnicity (OR, 1.71; 95% CI 1.13-2.57), elevated baseline creatinine (OR 2.80; 95% CI 1.63- 4.80) or troponin (OR 1.89; 95% 1.03-3.47), baseline lymphopenia (OR 2.19; 95% CI 1.61-2.97), presence of infiltrate by chest imaging (OR 3.16; 95% CI 1.96-5.10), and high SARS-CoV2 viral load (OR 1.53; 95% CI 1.17-2.00). Fatal cases had the lowest ratio of SARS-CoV-2 antibody to viral load levels compared to other trajectories over time (p=0.001). 589 survivors (51%) completed at least one survey at follow-up with 305 (52%) having at least one symptom consistent with PASC, most commonly dyspnea (56% among symptomatic patients). Female sex was the only associated risk factor for PASC.InterpretationIntegration of PCR cycle threshold, and antibody values with demographics, comorbidities, and laboratory/radiographic findings identified risk factors for 28-day outcome severity, though only female sex was associated with PASC. Longitudinal clinical phenotyping offers important insights, and provides a framework for immunophenotyping for acute and long COVID-19.FundingNIH.

Published
2022

7. Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants

Author

Alshammary, Hala, Banu, R., Farrugia, K., Gonzalez-Reiche, Ana Silvia, Paniz-Mondolfi, A., Polanco, J., Rosales, Romel, McGovern, Briana L., Rodriguez, M. Luis, Leiva-Rebollo, Rocio, Diaz-Tapia, Randy, Benjamin, Jared, Rai, Devendra K., Cardin, Rhonda D., Anderson, Annaliesa S., Sordillo, Emilia Mia, van Bakel, Harm, Simon, Viviana, García-Sastre, Adolfo, and White, Kris M.

Published
2024
Full Text
View/download PDF

8. The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization

Author

Karger, Amy B, Brien, James D, Christen, Jayne M, Dhakal, Santosh, Kemp, Troy J, Klein, Sabra L, Pinto, Ligia A, Premkumar, Lakshmanane, Roback, John D, Binder, Raquel A, Boehme, Karl W, Boppana, Suresh, Cordon-Cardo, Carlos, Crawford, James M, Daiss, John L, Dupuis, Alan P, Espino, Ana M, Firpo-Betancourt, Adolfo, Forconi, Catherine, Forrest, J Craig, Girardin, Roxie C, Granger, Douglas A, Granger, Steve W, Haddad, Natalie S, Heaney, Christopher D, Hunt, Danielle T, Kennedy, Joshua L, King, Christopher L, Krammer, Florian, Kruczynski, Kate, LaBaer, Joshua, Lee, F Eun-Hyung, Lee, William T, Liu, Shan-Lu, Lozanski, Gerard, Lucas, Todd, Mendu, Damodara Rao, Moormann, Ann M, Murugan, Vel, Okoye, Nkemakonam C, Pantoja, Petraleigh, Payne, Anne F, Park, Jin, Pinninti, Swetha, Pinto, Amelia K, Pisanic, Nora, Qiu, Ji, Sariol, Carlos A, Simon, Viviana, Song, Lusheng, Steffen, Tara L, Stone, E Taylor, Styer, Linda M, Suthar, Mehul S, Thomas, Stefani N, Thyagarajan, Bharat, Wajnberg, Ania, Yates, Jennifer L, and Sobhani, Kimia

Subjects
Clinical Research, Cancer, Emerging Infectious Diseases, Good Health and Well Being, Antibodies, Viral, COVID-19, COVID-19 Testing, Humans, SARS-CoV-2, Serologic Tests, SeroNet, assay harmonization, serology, Immunology, Microbiology
Abstract

In October 2020, the National Cancer Institute (NCI) Serological Sciences Network (SeroNet) was established to study the immune response to COVID-19, and "to develop, validate, improve, and implement serological testing and associated technologies" (https://www.cancer.gov/research/key-initiatives/covid-19/coronavirus-research-initiatives/serological-sciences-network). SeroNet is comprised of 25 participating research institutions partnering with the Frederick National Laboratory for Cancer Research (FNLCR) and the SeroNet Coordinating Center. Since its inception, SeroNet has supported collaborative development and sharing of COVID-19 serological assay procedures and has set forth plans for assay harmonization. To facilitate collaboration and procedure sharing, a detailed survey was sent to collate comprehensive assay details and performance metrics on COVID-19 serological assays within SeroNet. In addition, FNLCR established a protocol to calibrate SeroNet serological assays to reference standards, such as the U.S. severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology standard reference material and first WHO international standard (IS) for anti-SARS-CoV-2 immunoglobulin (20/136), to facilitate harmonization of assay reporting units and cross-comparison of study data. SeroNet institutions reported development of a total of 27 enzyme-linked immunosorbent assay (ELISA) methods, 13 multiplex assays, and 9 neutralization assays and use of 12 different commercial serological methods. FNLCR developed a standardized protocol for SeroNet institutions to calibrate these diverse serological assays to reference standards. In conclusion, SeroNet institutions have established a diverse array of COVID-19 serological assays to study the immune response to SARS-CoV-2 and vaccines. Calibration of SeroNet serological assays to harmonize results reporting will facilitate future pooled data analyses and study cross-comparisons. IMPORTANCE SeroNet institutions have developed or implemented 61 diverse COVID-19 serological assays and are collaboratively working to harmonize these assays using reference materials to establish standardized reporting units. This will facilitate clinical interpretation of serology results and cross-comparison of research data.

Published
2022

9. PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2

Author

Simon, Viviana, Kota, Vamsi, Bloomquist, Ryan F, Hanley, Hannah B, Forgacs, David, Pahwa, Savita, Pallikkuth, Suresh, Miller, Loren G, Schaenman, Joanna, Yeaman, Michael R, Manthei, David, Wolf, Joshua, Gaur, Aditya H, Estepp, Jeremie H, Srivastava, Komal, Carreño, Juan Manuel, Cuevas, Frans, Ellebedy, Ali H, Gordon, Aubree, Valdez, Riccardo, Cobey, Sarah, Reed, Elaine F, Kolhe, Ravindra, Thomas, Paul G, Schultz-Cherry, Stacey, Ross, Ted M, and Krammer, Florian

Subjects
Infectious Diseases, Prevention, Biodefense, Vaccine Related, Immunization, Pneumonia, Emerging Infectious Diseases, Pneumonia & Influenza, Lung, Infection, Good Health and Well Being, COVID-19, COVID-19 Vaccines, Humans, Reinfection, SARS-CoV-2, Seroepidemiologic Studies, antibodies, cohort study, reinfection, PARIS/SPARTA Study Group, Immunology, Microbiology
Abstract

To understand reinfection rates and correlates of protection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we established eight different longitudinal cohorts in 2020 under the umbrella of the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2)/SPARTA (SARS SeroPrevalence And Respiratory Tract Assessment) studies. Here, we describe the PARIS/SPARTA cohorts, the harmonized assays and analysis that are performed across the cohorts, as well as case definitions for SARS-CoV-2 infection and reinfection that have been established by the team of PARIS/SPARTA investigators. IMPORTANCE Determining reinfection rates and correlates of protection against SARS-CoV-2 infection induced by both natural infection and vaccination is of high significance for the prevention and control of coronavirus disease 2019 (COVID-19). Furthermore, understanding reinfections or infection after vaccination and the role immune escape plays in these scenarios will inform the need for updates of the current SARS-CoV-2 vaccines and help update guidelines suitable for the postpandemic world.

Published
2022

10. Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Author

Figueiredo, Jane C, Hirsch, Fred R, Kushi, Lawrence H, Nembhard, Wendy N, Crawford, James M, Mantis, Nicholas, Finster, Laurel, Merin, Noah M, Merchant, Akil, Reckamp, Karen L, Melmed, Gil Y, Braun, Jonathan, McGovern, Dermot, Parekh, Samir, Corley, Douglas A, Zohoori, Namvar, Amick, Benjamin C, Du, Ruofei, Gregersen, Peter K, Diamond, Betty, Taioli, Emanuela, Sariol, Carlos, Espino, Ana, Weiskopf, Daniela, Gifoni, Alba, Brien, James, Hanege, William, Lipsitch, Marc, Zidar, David A, McAlearney, Ann Scheck, Wajnberg, Ania, LaBaer, Joshua, Lewis, E Yvonne, Binder, Raquel A, Moormann, Ann M, Forconi, Catherine, Forrester, Sarah, Batista, Jennifer, Schieffelin, John, Kim, Dongjoo, Biancon, Giulia, VanOudenhove, Jennifer, Halene, Stephanie, Fan, Rong, Barouch, Dan H, Alter, Galit, Pinninti, Swetha, Boppana, Suresh B, Pati, Sunil K, Latting, Misty, Karaba, Andrew H, Roback, John, Sekaly, Rafick, Neish, Andrew, Brincks, Ahnalee M, Granger, Douglas A, Karger, Amy B, Thyagarajan, Bharat, Thomas, Stefani N, Klein, Sabra L, Cox, Andrea L, Lucas, Todd, Furr-Holden, Debra, Key, Kent, Jones, Nicole, Wrammerr, Jens, Suthar, Mehul, Wong, Serre Yu, Bowman, Natalie M, Simon, Viviana, Richardson, Lynne D, McBride, Russell, Krammer, Florian, Rana, Meenakshi, Kennedy, Joshua, Boehme, Karl, Forrest, Craig, Granger, Steve W, Heaney, Christopher D, Lapinski, Maria Knight, Wallet, Shannon, Baric, Ralph S, Schifanella, Luca, Lopez, Marcos, Fernández, Soledad, Kenah, Eben, Panchal, Ashish R, Britt, William J, Sanz, Iñaki, Dhodapkar, Madhav, Ahmed, Rafi, Bartelt, Luther A, Markmann, Alena J, Lin, Jessica T, Hagan, Robert S, Wolfgang, Matthew C, and Skarbinski, Jacek

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Pneumonia & Influenza, Vaccine Related, Emerging Infectious Diseases, Biodefense, Lung, Digestive Diseases, Infectious Diseases, Clinical Research, Pneumonia, Cancer, Pediatric, Prevention, Aetiology, 2.4 Surveillance and distribution, Good Health and Well Being, cohort, COVID-19, epidemiology, SARS-CoV-2, serosurveillance, SeroNet, Clinical sciences, Medical microbiology
Abstract

BackgroundGlobal efforts are needed to elucidate the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19), including seroprevalence, risk factors, and long-term sequelae, as well as immune responses after vaccination across populations and the social dimensions of prevention and treatment strategies.MethodsIn the United States, the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation's largest coordinated effort to study coronavirus disease 2019. The network comprises multidisciplinary researchers bridging gaps and fostering collaborations among immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policymakers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, human immunodeficiency virus, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including healthcare workers and first responders).ResultsSeveral studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes.ConclusionsIn this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.

Published
2022

11. Defining the risk of SARS-CoV-2 variants on immune protection

Author

DeGrace, Marciela M, Ghedin, Elodie, Frieman, Matthew B, Krammer, Florian, Grifoni, Alba, Alisoltani, Arghavan, Alter, Galit, Amara, Rama R, Baric, Ralph S, Barouch, Dan H, Bloom, Jesse D, Bloyet, Louis-Marie, Bonenfant, Gaston, Boon, Adrianus CM, Boritz, Eli A, Bratt, Debbie L, Bricker, Traci L, Brown, Liliana, Buchser, William J, Carreño, Juan Manuel, Cohen-Lavi, Liel, Darling, Tamarand L, Davis-Gardner, Meredith E, Dearlove, Bethany L, Di, Han, Dittmann, Meike, Doria-Rose, Nicole A, Douek, Daniel C, Drosten, Christian, Edara, Venkata-Viswanadh, Ellebedy, Ali, Fabrizio, Thomas P, Ferrari, Guido, Fischer, Will M, Florence, William C, Fouchier, Ron AM, Franks, John, García-Sastre, Adolfo, Godzik, Adam, Gonzalez-Reiche, Ana Silvia, Gordon, Aubree, Haagmans, Bart L, Halfmann, Peter J, Ho, David D, Holbrook, Michael R, Huang, Yaoxing, James, Sarah L, Jaroszewski, Lukasz, Jeevan, Trushar, Johnson, Robert M, Jones, Terry C, Joshi, Astha, Kawaoka, Yoshihiro, Kercher, Lisa, Koopmans, Marion PG, Korber, Bette, Koren, Eilay, Koup, Richard A, LeGresley, Eric B, Lemieux, Jacob E, Liebeskind, Mariel J, Liu, Zhuoming, Livingston, Brandi, Logue, James P, Luo, Yang, McDermott, Adrian B, McElrath, Margaret J, Meliopoulos, Victoria A, Menachery, Vineet D, Montefiori, David C, Mühlemann, Barbara, Munster, Vincent J, Munt, Jenny E, Nair, Manoj S, Netzl, Antonia, Niewiadomska, Anna M, O’Dell, Sijy, Pekosz, Andrew, Perlman, Stanley, Pontelli, Marjorie C, Rockx, Barry, Rolland, Morgane, Rothlauf, Paul W, Sacharen, Sinai, Scheuermann, Richard H, Schmidt, Stephen D, Schotsaert, Michael, Schultz-Cherry, Stacey, Seder, Robert A, Sedova, Mayya, Sette, Alessandro, Shabman, Reed S, Shen, Xiaoying, Shi, Pei-Yong, Shukla, Maulik, Simon, Viviana, Stumpf, Spencer, Sullivan, Nancy J, Thackray, Larissa B, and Theiler, James

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Biological Sciences, Emerging Infectious Diseases, Pneumonia, Vaccine Related, Pneumonia & Influenza, Infectious Diseases, Biodefense, Immunization, Biotechnology, Prevention, Lung, Prevention of disease and conditions, and promotion of well-being, 2.1 Biological and endogenous factors, 3.4 Vaccines, Aetiology, Infection, Good Health and Well Being, Animals, Biological Evolution, COVID-19, COVID-19 Vaccines, Humans, National Institute of Allergy and Infectious Diseases (U.S.), Pandemics, Pharmacogenomic Variants, SARS-CoV-2, United States, Virulence, General Science & Technology
Abstract

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.

Published
2022

12. Global post-translational modification profiling of HIV-1-infected cells reveals mechanisms of host cellular pathway remodeling

Author

Johnson, Jeffrey R, Crosby, David C, Hultquist, Judd F, Kurland, Andrew P, Adhikary, Prithy, Li, Donna, Marlett, John, Swann, Justine, Hüttenhain, Ruth, Verschueren, Erik, Johnson, Tasha L, Newton, Billy W, Shales, Michael, Simon, Viviana A, Beltrao, Pedro, Frankel, Alan D, Marson, Alexander, Cox, Jeffery S, Fregoso, Oliver I, Young, John AT, and Krogan, Nevan J

Subjects
HIV/AIDS, Infectious Diseases, Biotechnology, Genetics, Aetiology, 2.1 Biological and endogenous factors, Infection, HIV Infections, HIV Seropositivity, HIV-1, Humans, Protein Processing, Post-Translational, Proteomics, Ubiquitination, CP: Microbiology, CP: Molecular biology, b56, histone h1, phosphorylation, pp2a, proteomics, systems biology, ubiquitination, vif, vpr, Biochemistry and Cell Biology, Medical Physiology
Abstract

Viruses must effectively remodel host cellular pathways to replicate and evade immune defenses, and they must do so with limited genomic coding capacity. Targeting post-translational modification (PTM) pathways provides a mechanism by which viruses can broadly and rapidly transform a hostile host environment into a hospitable one. We use mass spectrometry-based proteomics to quantify changes in protein abundance and two PTM types-phosphorylation and ubiquitination-in response to HIV-1 infection with viruses harboring targeted deletions of a subset of HIV-1 genes. PTM analysis reveals a requirement for Aurora kinase activity in HIV-1 infection and identified putative substrates of a phosphatase that is degraded during infection. Finally, we demonstrate that the HIV-1 Vpr protein inhibits histone H1 ubiquitination, leading to defects in DNA repair.

Published
2022

13. Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission

Author

Escalera, Alba, Gonzalez-Reiche, Ana S, Aslam, Sadaf, Mena, Ignacio, Laporte, Manon, Pearl, Rebecca L, Fossati, Andrea, Rathnasinghe, Raveen, Alshammary, Hala, van de Guchte, Adriana, Farrugia, Keith, Qin, Yiren, Bouhaddou, Mehdi, Kehrer, Thomas, Zuliani-Alvarez, Lorena, Meekins, David A, Balaraman, Velmurugan, McDowell, Chester, Richt, Jürgen A, Bajic, Goran, Sordillo, Emilia Mia, Dejosez, Marion, Zwaka, Thomas P, Krogan, Nevan J, Simon, Viviana, Albrecht, Randy A, van Bakel, Harm, García-Sastre, Adolfo, and Aydillo, Teresa

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Emerging Infectious Diseases, Lung, Prevention, Biodefense, Vaccine Related, Aetiology, 2.2 Factors relating to the physical environment, Infection, Good Health and Well Being, COVID-19, Humans, Mutation, SARS-CoV-2, Spike Glycoprotein, Coronavirus, H655Y mutation, fusion, gamma, omicron, spike cleavage, syncytia formation, variants of concern, Microbiology, Immunology, Biochemistry and cell biology, Medical microbiology
Abstract

SARS-CoV-2 lineages have diverged into highly prevalent variants termed "variants of concern" (VOCs). Here, we characterized emerging SARS-CoV-2 spike polymorphisms in vitro and in vivo to understand their impact on transmissibility and virus pathogenicity and fitness. We demonstrate that the substitution S:655Y, represented in the gamma and omicron VOCs, enhances viral replication and spike protein cleavage. The S:655Y substitution was transmitted more efficiently than its ancestor S:655H in the hamster infection model and was able to outcompete S:655H in the hamster model and in a human primary airway system. Finally, we analyzed a set of emerging SARS-CoV-2 variants to investigate how different sets of mutations may impact spike processing. All VOCs tested exhibited increased spike cleavage and fusogenic capacity. Taken together, our study demonstrates that the spike mutations present in VOCs that become epidemiologically prevalent in humans are linked to an increase in spike processing and virus transmission.

Published
2022

15. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5

Author

Andre, Dalles, Bermúdez-González, Maria C., Bielak, Dominika, Cai, Gianna, Cognigni, Christian, Chen, Yuexing, Kang, Hyun Min, Kleiner, Giulio, Lyttle, Neko, Mauldin, Jacob, Morris, Sara, Nardulli, Jessica, Oostenink, Annika, Salimbangon, Ashley-Beathrese, Srivastava, Komal, Sullivan, Leeba, Van Kesteren, Morgan, Abbad, Anass, Yellin, Temima, Singh, Gagandeep, Fried, Miriam, Raskin, Ariel, Tcheou, Johnstone, Monahan, Brian, Gleason, Charles, Simon, Viviana, Carreño, Juan Manuel, and Krammer, Florian

Published
2024
Full Text
View/download PDF

16. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase

Author

Alshammary, Hala, Amoako, Angela A., Andre, Dalles, Awawda, Mahmoud, Bermúdez-González, Maria C., Beach, Katherine F., Bielak, Dominika, Cai, Gianna Y., Chernet, Rachel L., Cognigni, Christian, Chen, Yuexing, Eaker, Lily Q., Ferreri, Emily D., Floda, Daniel L., Fried, Miriam, Hamburger, Joshua Z., Jurczyszak, Denise, Kang, Hyun Min, Lyttle, Neko, Matthews, Julia C., Mauldin, Jacob, Mendez, Wanni A., Mischka, Jacob, Morris, Sara, Mulder, Lubbertus C.F., Nabeel, Ismail, Nardulli, Jessica R., Polanco, Jose, Oostenink, Annika, Rooker, Aria, Russo, Kayla T., Salimbangon, Ashley-Beathrese, Saksena, Miti S., Shin, Amber A., Sominsky, Levy A., Stadlbauer, Daniel, Sullivan, Leeba, van Kesteren, Morgan, Yellin, Temima, Wajnberg, Ania, Srivastava, Komal, Carreño, Juan Manuel, Gleason, Charles, Monahan, Brian, Singh, Gagandeep, Abbad, Anass, Tcheou, Johnstone, Raskin, Ariel, Kleiner, Giulio, van Bakel, Harm, Sordillo, Emilia Mia, Krammer, Florian, and Simon, Viviana

Published
2024
Full Text
View/download PDF

17. Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study

Author

Rouphael, Nadine, Maecker, Holden, Montgomery, Ruth R, Diray-Arce, Joann, Kleinstein, Steven H, Altman, Matthew C, Bosinger, Steven E, Eckalbar, Walter, Guan, Leying, Hough, Catherine L, Krammer, Florian, Langelier, Charles, Levy, Ofer, McEnaney, Kerry, Peters, Bjoern, Rahman, Adeeb, Rajan, Jayant V, Sigelman, Steven, Steen, Hanno, van Bakel, Harm, Ward, Alyssa, Wilson, Michael R, Woodruff, Prescott, Zamecnik, Colin R, Augustine, Alison D, Ozonoff, Al, Reed, Elaine F, Becker, Patrice M, Higuita, Nelson Agudelo, Atkinson, Mark A, Baden, Lindsey R, Bime, Christian, Brakenridge, Scott C, Calfee, Carolyn S, Cairns, Charles B, Corry, David, Davis, Mark M, Ehrlich, Lauren IR, Haddad, Elias K, Erle, David J, Fernandez-Sesma, Ana, Hafler, David A, Kheradmand, Farrah, Kraft, Monica, McComsey, Grace A, Melamed, Esther, Messer, William, Metcalf, Jordan, Nadeau, Kari C, Pulendran, Bali, Sarwal, Minnie, Schaenman, Joanna, Sekaly, Rafick, Shaw, Albert C, and Simon, Viviana

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Biomarkers, COVID-19, Computational Biology, Data Analysis, Gene Expression Profiling, Hospitalization, Humans, Immunophenotyping, Longitudinal Studies, Molecular Diagnostic Techniques, Prospective Studies, Proteomics, SARS-CoV-2, United States, IMPACC Manuscript Writing Team, IMPACC Network Steering Committee, Clinical sciences, Immunology
Abstract

The IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective longitudinal study designed to enroll 1000 hospitalized patients with COVID-19 (NCT04378777). IMPACC collects detailed clinical, laboratory and radiographic data along with longitudinal biologic sampling of blood and respiratory secretions for in depth testing. Clinical and lab data are integrated to identify immunologic, virologic, proteomic, metabolomic and genomic features of COVID-19-related susceptibility, severity and disease progression. The goals of IMPACC are to better understand the contributions of pathogen dynamics and host immune responses to the severity and course of COVID-19 and to generate hypotheses for identification of biomarkers and effective therapeutics, including optimal timing of such interventions. In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans.

Published
2021

18. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma

Author

Alshammary, Hala, Andre, Dalles, Banu, Radhika, Beach, Katherine, Bermúdez-González, María Carolina, Chari, Ajai, Chen, Yuexing, Cho, Hearn, Firpo, Adolfo, Gonzalez-Reiche, Ana Silvia, Kim, Eun Hye, Kleiner, Giulio, Krammer, Florian, Mauldin, Jacob, Mendu, Rao, Monahan, Brian, Richard, Shambavi, Richter, Joshua, Rodriguez, Cesar, Rossi, Adrianna, Salimbangon, Ashley, Sanchez, Laryssa, Verina, Daniel, Aleman, Adolfo, van Kesteren, Morgan, Zajdman, Ariel Kogan, Srivastava, Komal, Cognigni, Christian, Mischka, Jacob, Chen, Lucia Y., Upadhyaya, Bhaskar, Serebryakova, Kseniya, Nardulli, Jessica R., Lyttle, Neko, Kappes, Katerina, Jackson, Hayley, Gleason, Charles R., Oostenink, Annika, Cai, Gianna Y., Van Oekelen, Oliver, van Bakel, Harm, Sordillo, Emilia Mia, Cordon-Cardo, Carlos, Merad, Miriam, Jagannath, Sundar, Wajnberg, Ania, Simon, Viviana, and Parekh, Samir

Published
2023
Full Text
View/download PDF

19. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study

Author

Amoako, Angela, Andre, Dalles, van Bakel, Harm, Cognini, Christian C., Gleason, Charles, Gonzales-Reiche, Ana, van Kesteren, Morgan, Kleiner, Giulio, Lyttle, Neko, Mauldin, Jacob D., Monahan, Brian C., Nardulli, Jessica R., Oostenink, Annika, Paniz-Mondolfi, Alberto, Polanco, Jose, Ramírez, Juan David, Rooker, Aria, Sordillo, Emilia Mia, Srivastava, Komal, Cohn, Hallie, Bloom, Nathaniel, Cai, Gianna Y, Clark, Jordan J, Tarke, Alison, Bermúdez-González, Maria C, Altman, Deena R, Lugo, Luz Amarilis, Lobo, Francisco Pereira, Marquez, Susanna, Chen, Jin-Qiu, Ren, Wenlin, Qin, Lili, Yates, Jennifer L, Hunt, Danielle T, Lee, William T, Crotty, Shane, Krammer, Florian, Grifoni, Alba, Sette, Alessandro, Simon, Viviana, and Coelho, Camila H

Published
2023
Full Text
View/download PDF

20. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Author

Dan, Jennifer M, Mateus, Jose, Kato, Yu, Hastie, Kathryn M, Yu, Esther Dawen, Faliti, Caterina E, Grifoni, Alba, Ramirez, Sydney I, Haupt, Sonya, Frazier, April, Nakao, Catherine, Rayaprolu, Vamseedhar, Rawlings, Stephen A, Peters, Bjoern, Krammer, Florian, Simon, Viviana, Saphire, Erica Ollmann, Smith, Davey M, Weiskopf, Daniela, Sette, Alessandro, and Crotty, Shane

Subjects
Biomedical and Clinical Sciences, Immunology, Immunization, Lung, Prevention, Pneumonia, Pneumonia & Influenza, Emerging Infectious Diseases, Vaccine Related, Infectious Diseases, Biodefense, Infection, Inflammatory and immune system, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antibodies, Neutralizing, Antibodies, Viral, B-Lymphocytes, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, COVID-19, Cross-Sectional Studies, Female, Humans, Immunologic Memory, Longitudinal Studies, Male, Middle Aged, Spike Glycoprotein, Coronavirus, United States, Young Adult, General Science & Technology
Abstract

Understanding immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for improving diagnostics and vaccines and for assessing the likely future course of the COVID-19 pandemic. We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 samples at ≥6 months after infection. Immunoglobulin G (IgG) to the spike protein was relatively stable over 6+ months. Spike-specific memory B cells were more abundant at 6 months than at 1 month after symptom onset. SARS-CoV-2-specific CD4+ T cells and CD8+ T cells declined with a half-life of 3 to 5 months. By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.

Published
2021

21. Immunological memory to SARS-CoV-2 assessed for up to eight months after infection

Author

Dan, Jennifer M, Mateus, Jose, Kato, Yu, Hastie, Kathryn M, Yu, Esther Dawen, Faliti, Caterina E, Grifoni, Alba, Ramirez, Sydney I, Haupt, Sonya, Frazier, April, Nakao, Catherine, Rayaprolu, Vamseedhar, Rawlings, Stephen A, Peters, Bjoern, Krammer, Florian, Simon, Viviana, Saphire, Erica Ollmann, Smith, Davey M, Weiskopf, Daniela, Sette, Alessandro, and Crotty, Shane

Subjects
Biomedical and Clinical Sciences, Immunology, Vaccine Related, Prevention, Lung, Immunization, Biodefense, Emerging Infectious Diseases, Infectious Diseases, Pneumonia, Pneumonia & Influenza, Inflammatory and immune system, Infection, Good Health and Well Being
Abstract

Understanding immune memory to SARS-CoV-2 is critical for improving diagnostics and vaccines, and for assessing the likely future course of the COVID-19 pandemic. We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 samples at ≥ 6 months post-infection. IgG to the Spike protein was relatively stable over 6+ months. Spike-specific memory B cells were more abundant at 6 months than at 1 month post symptom onset. SARS-CoV-2-specific CD4 + T cells and CD8 + T cells declined with a half-life of 3-5 months. By studying antibody, memory B cell, CD4 + T cell, and CD8 + T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.

Published
2020

22. Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients

Author

Abraham, James, Adkisson, Michael, Albert, Marisa, Altamirano, Luz Torres, Alvarenga, Bonny, Anderson, Matthew L., Anderson, Evan J., Arnett, Azlann, Asashima, Hiromitsu, Atkinson, Mark A., Baden, Lindsey R., Barton, Brenda, Beach, Katherine, Beagle, Elizabeth, Becker, Patrice M., Bell, Matthew R., Bernui, Mariana, Bime, Christian, Boddapati, Arun Kumar, Booth, J. Leland, Borresen, Brittney, Brakenridge, Scott C., Bristow, Laurel, Bryant, Robert, Calfee, Carolyn S., Carreño, Juan Manuel, Carrillo, Sidney, Chak, Suzanna, Chang, Iris, Connors, Jennifer, Conway, Michelle, Corry, David B., Cowan, David, Croen, Brett, Dela Cruz, Charles S., Cusimano, Gina, Eaker, Lily, Edwards, Carolyn, Ehrlich, Lauren I.R., Elashoff, David, Erickson, Heidi, Erle, David J., Farhadian, Shelli, Farrugia, Keith, Fatou, Benoit, Fernandes, Andrea, Fernandez-Sesma, Ana, Fragiadakis, Gabriela K., Furukawa, Sara, Geltman, Janelle N., Ghale, Rajani, Bermúdez González, Maria Carolina, Goonewardene, I. Michael, Guerrero, Estella Sanchez, Guirgis, Faheem W., Hafler, David A., Hamilton, Sydney, Harris, Paul, Hayati, Arash Nemati, Hendrickson, Carolyn M., Agudelo Higuita, Nelson I., Hodder, Thomas, Holland, Steven M., Hough, Catherine L., Huerta, Christopher, Hurley, Kerin C., Hutton, Scott R., Iwasaki, Akiko, Jauregui, Alejandra, Jha, Meenakshi, Johnson, Brandi, Joyner, David, Kangelaris, Kirsten N., Kelly, Geoffrey, Khalil, Zain, Khan, Zenab, Kheradmand, Farrah, Kim, James N., Kimura, Hiroki, Ko, Albert I., Kohr, Bernard, Kraft, Monica, Krummel, Matthew, Kutzler, Michele A., Lasky-Su, Jessica, Lee, Serena, Lee, Deanna, Leipold, Michael, Lentucci, Claudia, Leroux, Carolyn, Lin, Edward, Liu, Shanshan, Love, Christina, Lu, Zhengchun, Maliskova, Lenka, Manning, Brittany Roth, Manohar, Monali, Martens, Mark, McComsey, Grace A., McEnaney, Kerry, McLin, Renee, Melamed, Esther, Melnyk, Nataliya, Mendez, Kevin, Messer, William B., Metcalf, Jordan P., Michelotti, Gregory, Mick, Eran, Mohanty, Subhasis, Mosier, Jarrod, Mulder, Lubbertus C.F., Murphy, Maimouna, Nadeau, Kari R.C., Nelson, Ebony, Nelson, Allison, Nguyen, Viet, Oberhaus, Jordan, Panganiban, Bernadine, Pellegrini, Kathryn L., Pickering, Harry C., Powell, Debra L., Presnell, Scott, Pulendran, Bali, Rahman, Adeeb H., Rashid, Ahmad Sadeed, Raskin, Ariel, Reed, Elaine F., Ribeiro, Susan Pereira, Rivera, Adreanne M., Rogers, Jacob E., Rogers, Angela, Rogowski, Brandon, Rooks, Rebecca, Rosenberg-Hasson, Yael, Rothman, Jessica, Rousseau, Justin F., Salehi-Rad, Ramin, Saluvan, Mehmet, Samaha, Hady, Schaenman, Joanna, Schunk, Ron, Semenza, Nicholas C., Sen, Subha, Sevransky, Jonathan, Seyfert-Margolis, Vicki, Shaheen, Tanzia, Shaw, Albert C., Sieg, Scott, Siegel, Sarah A.R., Sigal, Natalia, Siles, Nadia, Simmons, Brent, Simon, Viviana, Singh, Gagandeep, Sinko, Lauren, Smith, Cecilia M., Smolen, Kinga K., Song, Li-Zhen, Srivastava, Komal, Sullivan, Peter, Syphurs, Caitlin, Tcheou, Johnstone, Tegos, George P., Tharp, Greg K., Tong, Alexandra, Tsitsiklis, Alexandra, Ungaro, Ricardo F., Vaysman, Tatyana, Viode, Arthur, Vita, Randi, Wang, Xiaomei, Ward, Alyssa, Ward, Dawn C., Willmore, Andrew, Woloszczuk, Kyra, Wong, Kari, Woodruff, Prescott G., Xu, Leqi, van Haren, Simon, van de Guchte, Adriana, Zhao, Yujiao, Diray-Arce, Joann, Fourati, Slim, Doni Jayavelu, Naresh, Patel, Ravi, Maguire, Cole, Chang, Ana C., Dandekar, Ravi, Qi, Jingjing, Lee, Brian H., van Zalm, Patrick, Schroeder, Andrew, Chen, Ernie, Konstorum, Anna, Brito, Anderson, Gygi, Jeremy P., Kho, Alvin, Chen, Jing, Pawar, Shrikant, Gonzalez-Reiche, Ana Silvia, Hoch, Annmarie, Milliren, Carly E., Overton, James A., Westendorf, Kerstin, Cairns, Charles B., Rouphael, Nadine, Bosinger, Steven E., Kim-Schulze, Seunghee, Krammer, Florian, Rosen, Lindsey, Grubaugh, Nathan D., van Bakel, Harm, Wilson, Michael, Rajan, Jayant, Steen, Hanno, Eckalbar, Walter, Cotsapas, Chris, Langelier, Charles R., Levy, Ofer, Altman, Matthew C., Maecker, Holden, Montgomery, Ruth R., Haddad, Elias K., Sekaly, Rafick P., Esserman, Denise, Ozonoff, Al, Augustine, Alison D., Guan, Leying, Peters, Bjoern, and Kleinstein, Steven H.

Published
2023
Full Text
View/download PDF

23. Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis

Author

Kehrer, Thomas, Cupic, Anastasija, Ye, Chengjin, Yildiz, Soner, Bouhaddou, Mehdi, Crossland, Nicholas A., Barrall, Erika A., Cohen, Phillip, Tseng, Anna, Çağatay, Tolga, Rathnasinghe, Raveen, Flores, Daniel, Jangra, Sonia, Alam, Fahmida, Mena, Ignacio, Aslam, Sadaf, Saqi, Anjali, Rutkowska, Magdalena, Ummadi, Manisha R., Pisanelli, Giuseppe, Richardson, R. Blake, Veit, Ethan C., Fabius, Jacqueline M., Soucheray, Margaret, Polacco, Benjamin J., Ak, Baran, Marin, Arturo, Evans, Matthew J., Swaney, Danielle L., Gonzalez-Reiche, Ana S., Sordillo, Emilia M., van Bakel, Harm, Simon, Viviana, Zuliani-Alvarez, Lorena, Fontoura, Beatriz M.A., Rosenberg, Brad R., Krogan, Nevan J., Martinez-Sobrido, Luis, García-Sastre, Adolfo, and Miorin, Lisa

Published
2023
Full Text
View/download PDF

25. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants

Author

Duty, J. Andrew, Kraus, Thomas, Zhou, Heyue, Zhang, Yanliang, Shaabani, Namir, Yildiz, Soner, Du, Na, Singh, Alok, Miorin, Lisa, Li, Donghui, Stegman, Karen, Ophir, Sabrina, Cao, Xia, Atanasoff, Kristina, Lim, Reyna, Mena, Ignacio, Bouvier, Nicole M., Kowdle, Shreyas, Carreño, Juan Manuel, Rivero-Nava, Laura, Raskin, Ariel, Moreno, Elena, Johnson, Sachi, Rathnasinghe, Raveen, Pai, Chin I., Kehrer, Thomas, Cabral, Elizabeth Paz, Jangra, Sonia, Healy, Laura, Singh, Gagandeep, Warang, Prajakta, Simon, Viviana, Sordillo, Emilia Mia, van Bakel, Harm, Liu, Yonghong, Sun, Weina, Kerwin, Lisa, Teijaro, John, Schotsaert, Michael, Krammer, Florian, Bresson, Damien, García-Sastre, Adolfo, Fu, Yanwen, Lee, Benhur, Powers, Colin, Moran, Thomas, Ji, Henry, Tortorella, Domenico, and Allen, Robert

Published
2022
Full Text
View/download PDF

27. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Author

Halfmann, Peter J., Iida, Shun, Iwatsuki-Horimoto, Kiyoko, Maemura, Tadashi, Kiso, Maki, Scheaffer, Suzanne M., Darling, Tamarand L., Joshi, Astha, Loeber, Samantha, Singh, Gagandeep, Foster, Stephanie L., Ying, Baoling, Case, James Brett, Chong, Zhenlu, Whitener, Bradley, Moliva, Juan, Floyd, Katharine, Ujie, Michiko, Nakajima, Noriko, Ito, Mutsumi, Wright, Ryan, Uraki, Ryuta, Warang, Prajakta, Gagne, Matthew, Li, Rong, Sakai-Tagawa, Yuko, Liu, Yanan, Larson, Deanna, Osorio, Jorge E., Hernandez-Ortiz, Juan P., Henry, Amy R., Ciuoderis, Karl, Florek, Kelsey R., Patel, Mit, Odle, Abby, Wong, Lok-Yin Roy, Bateman, Allen C., Wang, Zhongde, Edara, Venkata-Viswanadh, Chong, Zhenlu, Franks, John, Jeevan, Trushar, Fabrizio, Thomas, DeBeauchamp, Jennifer, Kercher, Lisa, Seiler, Patrick, Gonzalez-Reiche, Ana Silvia, Sordillo, Emilia Mia, Chang, Lauren A., van Bakel, Harm, Simon, Viviana, Douek, Daniel C., Sullivan, Nancy J., Thackray, Larissa B., Ueki, Hiroshi, Yamayoshi, Seiya, Imai, Masaki, Perlman, Stanley, Webby, Richard J., Seder, Robert A., Suthar, Mehul S., García-Sastre, Adolfo, Schotsaert, Michael, Suzuki, Tadaki, Boon, Adrianus C. M., Diamond, Michael S., and Kawaoka, Yoshihiro

Published
2022
Full Text
View/download PDF

29. Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera

Author

Rathnasinghe, Raveen, Jangra, Sonia, Ye, Chengjin, Cupic, Anastasija, Singh, Gagandeep, Martínez-Romero, Carles, Mulder, Lubbertus C. F., Kehrer, Thomas, Yildiz, Soner, Choi, Angela, Yeung, Stephen T., Mena, Ignacio, Gillespie, Virginia, De Vrieze, Jana, Aslam, Sadaf, Stadlbauer, Daniel, Meekins, David A., McDowell, Chester D., Balaraman, Velmurugan, Corley, Michael J., Richt, Juergen A., De Geest, Bruno G., Miorin, Lisa, Krammer, Florian, Martinez-Sobrido, Luis, Simon, Viviana, García-Sastre, Adolfo, and Schotsaert, Michael

Published
2022
Full Text
View/download PDF

33. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Author

Carreño, Juan Manuel, Alshammary, Hala, Tcheou, Johnstone, Singh, Gagandeep, Raskin, Ariel J., Kawabata, Hisaaki, Sominsky, Levy A., Clark, Jordan J., Adelsberg, Daniel C., Bielak, Dominika A., Gonzalez-Reiche, Ana Silvia, Dambrauskas, Nicholas, Vigdorovich, Vladimir, Srivastava, Komal, Sather, D. Noah, Sordillo, Emilia Mia, Bajic, Goran, van Bakel, Harm, Simon, Viviana, and Krammer, Florian

Published
2022
Full Text
View/download PDF

34. Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model.

Author

Bailey, Mark J, Duehr, James, Dulin, Harrison, Broecker, Felix, Brown, Julia A, Arumemi, Fortuna O, Bermúdez González, Maria C, Leyva-Grado, Victor H, Evans, Matthew J, Simon, Viviana, Lim, Jean K, Krammer, Florian, Hai, Rong, Palese, Peter, and Tan, Gene S

Subjects
Jurkat Cells, Vero Cells, Animals, Mice, Knockout, Humans, Mice, Disease Models, Animal, Receptors, IgG, Recombinant Proteins, Viral Nonstructural Proteins, Viral Vaccines, Antibodies, Monoclonal, Antibodies, Viral, Neutralization Tests, STAT2 Transcription Factor, HEK293 Cells, Zika Virus, Zika Virus Infection, Chlorocebus aethiops, Knockout, Cercopithecus aethiops, Disease Models, Animal, Receptors, IgG, Antibodies, Monoclonal, Viral, Immunization, Prevention, Vaccine Related, Biotechnology, Vector-Borne Diseases, Emerging Infectious Diseases, Infectious Diseases, Biodefense, Rare Diseases, 2.1 Biological and endogenous factors, Infection
Abstract

Zika virus is a mosquito-borne flavivirus closely related to dengue virus that can cause severe disease in humans, including microcephaly in newborns and Guillain-Barré syndrome in adults. Specific treatments and vaccines for Zika virus are not currently available. Here, we isolate and characterize four monoclonal antibodies (mAbs) from an infected patient that target the non-structural protein NS1. We show that while these antibodies are non-neutralizing, NS1-specific mAbs can engage FcγR without inducing antibody dependent enhancement (ADE) of infection in vitro. Moreover, we demonstrate that mAb AA12 has protective efficacy against lethal challenges of African and Asian lineage strains of Zika virus in Stat2-/- mice. Protection is Fc-dependent, as a mutated antibody unable to activate known Fc effector functions or complement is not protective in vivo. This study highlights the importance of the ZIKV NS1 protein as a potential vaccine antigen.

Published
2018

35. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays

Author

Mühlemann, Barbara, primary, Wilks, Samuel H., additional, Baracco, Lauren, additional, Bekliz, Meriem, additional, Carreño, Juan Manuel, additional, Corman, Victor M., additional, Davis-Gardner, Meredith E., additional, Dejnirattisai, Wanwisa, additional, Diamond, Michael S., additional, Douek, Daniel C., additional, Drosten, Christian, additional, Eckerle, Isabella, additional, Edara, Venkata-Viswanadh, additional, Ellis, Madison, additional, Fouchier, Ron A. M., additional, Frieman, Matthew, additional, Godbole, Sucheta, additional, Haagmans, Bart, additional, Halfmann, Peter J., additional, Henry, Amy R., additional, Jones, Terry C., additional, Katzelnick, Leah C., additional, Kawaoka, Yoshihiro, additional, Kimpel, Janine, additional, Krammer, Florian, additional, Lai, Lilin, additional, Liu, Chang, additional, Lusvarghi, Sabrina, additional, Meyer, Benjamin, additional, Mongkolsapaya, Juthathip, additional, Montefiori, David C., additional, Mykytyn, Anna, additional, Netzl, Antonia, additional, Pollett, Simon, additional, Rössler, Annika, additional, Screaton, Gavin R., additional, Shen, Xiaoying, additional, Sigal, Alex, additional, Simon, Viviana, additional, Subramanian, Rahul, additional, Supasa, Piyada, additional, Suthar, Mehul S., additional, Türeli, Sina, additional, Wang, Wei, additional, Weiss, Carol D., additional, and Smith, Derek J., additional

Published
2024
Full Text
View/download PDF

36. Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities

Author

Klingler, Jéromine, primary, Kowdle, Shreyas, additional, Bandres, Juan C., additional, Emami-Gorizi, Rozita, additional, Alvarez, Raymond A., additional, Rao, Priyanka G., additional, Amanat, Fatima, additional, Gleason, Charles, additional, Kleiner, Giulio, additional, Simon, Viviana, additional, Edelstein, Alexis, additional, Perandones, Claudia, additional, Upadhyay, Chitra, additional, Lee, Benhur, additional, and Hioe, Catarina E., additional

Published
2024
Full Text
View/download PDF

38. SARS-CoV-2 in Transit: Characterization of SARS-CoV-2 Genomes From Venezuelan Migrants in Colombia

Author

Patiño, Luz H., Ballesteros, Nathalia, Muñoz, Marina, Castañeda, Sergio, Hernández, Carolina, Gomez, Sergio, Florez, Carolina, Rico, Angelica, Pardo, Liseth, Hernandez-Pereira, Carlos E., Delgado-Noguera, Lourdes, Grillet, Maria E., Hernandez, Matthew M., Khan, Zenab, van de Guchte, Adriana, Dutta, Jayeeta, Gonzalez-Reiche, Ana S, Simon, Viviana, van Bakel, Harm, Sordillo, Emilia Mia, Ramírez, Juan David, and Paniz-Mondolfi, Alberto E.

Published
2021
Full Text
View/download PDF

39. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants

Author

Changrob, Siriruk, Halfmann, Peter J., Liu, Hejun, Torres, Jonathan L., McGrath, Joshua J.C., Ozorowski, Gabriel, Li, Lei, Wilbanks, G. Dewey, Kuroda, Makoto, Maemura, Tadashi, Huang, Min, Zheng, Nai-Ying, Turner, Hannah L., Erickson, Steven A., Fu, Yanbin, Yasuhara, Atsuhiro, Singh, Gagandeep, Monahan, Brian, Mauldin, Jacob, Srivastava, Komal, Simon, Viviana, Krammer, Florian, Sather, D. Noah, Ward, Andrew B., Wilson, Ian A., Kawaoka, Yoshihiro, and Wilson, Patrick C.

Subjects
Viral antibodies -- Health aspects, Antibodies -- Health aspects, Health care industry
Abstract

The rapid evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants has emphasized the need to identify antibodies with broad neutralizing capabilities to inform future monoclonal therapies and vaccination strategies. Herein, we identified S728-1157, a broadly neutralizing antibody (bnAb) targeting the receptor-binding site (RBS) that was derived from an individual previously infected with WT SARS-CoV-2 prior to the spread of variants of concern (VOCs). S728-1157 demonstrated broad cross-neutralization of all dominant variants, including D614G, Beta, Delta, Kappa, Mu, and Omicron (BA.1/BA.2/BA.2.75/BA.4/BA.5/BL.1/XBB). Furthermore, S728-1157 protected hamsters against in vivo challenges with WT, Delta, and BA.1 viruses. Structural analysis showed that this antibody targets a class 1/RBS-A epitope in the receptor binding domain via multiple hydrophobic and polar interactions with its heavy chain complementarity determining region 3 (CDR-H3), in addition to common motifs in CDR-H1/CDR-H2 of class 1/RBS-A antibodies. Importantly, this epitope was more readily accessible in the open and prefusion state, or in the hexaproline (6P)-stabilized spike constructs, as compared with diproline (2P) constructs. Overall, S728-1157 demonstrates broad therapeutic potential and may inform target-driven vaccine designs against future SARS-CoV-2 variants., Introduction Since the start of the pandemic in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has led to over 660 million cases of coronavirus disease 2019 [...]

Published
2023
Full Text
View/download PDF

40. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Author

Ahmed, Bulbul, Altman, Deena, Amoako, Angela, Awawda, Mahmoud, Beach, Katherine, Bermúdez-González, Carolina, Chernet, Rachel, Eaker, Lily, Fabre, Shelcie, Ferreri, Emily D., Floda, Daniel, Gleason, Charles, Kleiner, Giulio, Jurczyszak, Denise, Matthews, Julia, Mendez, Wanni, Mulder, Lubbertus C.F., Polanco, Jose, Russo, Kayla, Salimbangon, Ashley, Saksena, Miti, Shin, Amber S., Sominsky, Levy, Suthakaran, Sayahi, Wajnberg, Ania, Amanat, Fatima, Thapa, Mahima, Lei, Tinting, Ahmed, Shaza M. Sayed, Adelsberg, Daniel C., Carreño, Juan Manuel, Strohmeier, Shirin, Schmitz, Aaron J., Zafar, Sarah, Zhou, Julian Q., Rijnink, Willemijn, Alshammary, Hala, Borcherding, Nicholas, Reiche, Ana Gonzalez, Srivastava, Komal, Sordillo, Emilia Mia, van Bakel, Harm, Turner, Jackson S., Bajic, Goran, Simon, Viviana, Ellebedy, Ali H., and Krammer, Florian

Published
2021
Full Text
View/download PDF

41. The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility

Author

Watanabe, Susan M, Simon, Viviana, Durham, Natasha D, Kemp, Brittney R, Machihara, Satoshi, Kemal, Kimdar Sherefa, Shi, Binshan, Foley, Brian, Li, Hongru, Chen, Benjamin K, Weiser, Barbara, Burger, Harold, Anastos, Kathryn, Chen, Chaoping, and Carter, Carol A

Subjects
Microbiology, Biological Sciences, Genetics, HIV/AIDS, Aetiology, 2.1 Biological and endogenous factors, Infection, Antiretroviral Therapy, Highly Active, Female, HEK293 Cells, HIV Infections, HIV Protease, HIV Protease Inhibitors, HIV-1, Humans, Mutation, Polymorphism, Genetic, Reproductive Tract Infections, Transcription Factors, Virus Release, Virus Replication, gag Gene Products, Human Immunodeficiency Virus, HIV Gag, HIV protease, Protease inhibitors, Late domain, Anti-retroviral drugs, ESCRT, Clinical Sciences, Virology
Abstract

BackgroundThe p6 region of the HIV-1 structural precursor polyprotein, Gag, contains two motifs, P7TAP11 and L35YPLXSL41, designated as late (L) domain-1 and -2, respectively. These motifs bind the ESCRT-I factor Tsg101 and the ESCRT adaptor Alix, respectively, and are critical for efficient budding of virus particles from the plasma membrane. L domain-2 is thought to be functionally redundant to PTAP. To identify possible other functions of L domain-2, we examined this motif in dominant viruses that emerged in a group of 14 women who had detectable levels of HIV-1 in both plasma and genital tract despite a history of current or previous antiretroviral therapy.ResultsRemarkably, variants possessing mutations or rare polymorphisms in the highly conserved L domain-2 were identified in seven of these women. A mutation in a conserved residue (S40A) that does not reduce Gag interaction with Alix and therefore did not reduce budding efficiency was further investigated. This mutation causes a simultaneous change in the Pol reading frame but exhibits little deficiency in Gag processing and virion maturation. Whether introduced into the HIV-1 NL4-3 strain genome or a model protease (PR) precursor, S40A reduced production of mature PR. This same mutation also led to high level detection of two extended forms of PR that were fairly stable compared to the WT in the presence of IDV at various concentrations; one of the extended forms was effective in trans processing even at micromolar IDV.ConclusionsOur results indicate that L domain-2, considered redundant in vitro, can undergo mutations in vivo that significantly alter PR function. These may contribute fitness benefits in both the absence and presence of PR inhibitor.

Published
2016

42. Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination

Author

Clark, Jordan, primary, Hoxie, Irene, additional, Adelsberg, Daniel C., additional, Sapse, Iden A., additional, Andreata-Santos, Robert, additional, Yong, Jeremy S., additional, Amanat, Fatima, additional, Tcheou, Johnstone, additional, Raskin, Ariel, additional, Singh, Gagandeep, additional, González-Domínguez, Irene, additional, Edgar, Julia E., additional, Bournazos, Stylianos, additional, Sun, Weina, additional, Carreño, Juan Manuel, additional, Simon, Viviana, additional, Ellebedy, Ali H., additional, Bajic, Goran, additional, and Krammer, Florian, additional

Published
2024
Full Text
View/download PDF

44. A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells

Author

Hultquist, Judd F, Schumann, Kathrin, Woo, Jonathan M, Manganaro, Lara, McGregor, Michael J, Doudna, Jennifer, Simon, Viviana, Krogan, Nevan J, and Marson, Alexander

Subjects
Biological Sciences, Biotechnology, Genetics, Sexually Transmitted Infections, HIV/AIDS, Infectious Diseases, 2.1 Biological and endogenous factors, Aetiology, Infection, CD4-Positive T-Lymphocytes, CRISPR-Cas Systems, Cells, Cultured, Gene Editing, Gene Knockout Techniques, HIV Infections, HIV-1, Host-Pathogen Interactions, Humans, Intercellular Signaling Peptides and Proteins, Receptors, CXCR4, Receptors, CXCR5, Reproducibility of Results, Ribonucleoproteins, beta Karyopherins, CCR5, CRISPR/Cas9, CXCR4, HIV integrase, LEDGF, TNPO3, genome editing, host dependency factors, host-pathogen interactions, primary T cells, Biochemistry and Cell Biology, Medical Physiology, Biological sciences
Abstract

New genetic tools are needed to understand the functional interactions between HIV and human host factors in primary cells. We recently developed a method to edit the genome of primary CD4+ T cells by electroporation of CRISPR/Cas9 ribonucleoproteins (RNPs). Here, we adapted this methodology to a high-throughput platform for the efficient, arrayed editing of candidate host factors. CXCR4 or CCR5 knockout cells generated with this method are resistant to HIV infection in a tropism-dependent manner, whereas knockout of LEDGF or TNPO3 results in a tropism-independent reduction in infection. CRISPR/Cas9 RNPs can furthermore edit multiple genes simultaneously, enabling studies of interactions among multiple host and viral factors. Finally, in an arrayed screen of 45 genes associated with HIV integrase, we identified several candidate dependency/restriction factors, demonstrating the power of this approach as a discovery platform. This technology should accelerate target validation for pharmaceutical and cell-based therapies to cure HIV infection.

Published
2016

45. Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection (vol 44, pg 46, 2016)

Author

Heaton, Nicholas S, Moshkina, Natasha, Fenouil, Romain, Gardner, Thomas J, Aguirre, Sebastian, Shah, Priya S, Zhao, Nan, Manganaro, Lara, Hultquist, Judd F, Noel, Justine, Sachs, David, Hamilton, Jennifer, Leon, Paul E, Chawdury, Amit, Tripathi, Shashank, Melegari, Camilla, Campisi, Laura, Hai, Rong, Metreveli, Giorgi, Gamarnik, Andrea V, Garcia-Sastre, Adolfo, Greenbaum, Benjamin, Simon, Viviana, Fernandez-Sesma, Ana, Krogan, Nevan J, Mulder, Lubbertus CF, van Bakel, Harm, Tortorella, Domenico, Taunton, Jack, Palese, Peter, and Marazzi, Ivan

Subjects
Immunology
Published
2016

46. SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023

Author

Carreno Quiroz, Juan Manuel, primary, Wagner, Abram, additional, Monahan, Brian, additional, Floda, Daniel, additional, Gonzalez-Reiche, Ana S., additional, Tcheou, Johnstone, additional, Raskin, Ariel, additional, Bielak, Dominika, additional, Singh, Gagandeep, additional, Morris, Sara, additional, Fried, Miriam, additional, Yellin, Temima, additional, Sullivan, Leeba, additional, Study Group, PARIS, additional, Sordillo, Emilia M, additional, Gordon, Aubree, additional, van Bakel, Harm, additional, Simon, Viviana, additional, and Krammer, Florian, additional

Published
2023
Full Text
View/download PDF

47. Corrigendum to “Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study” [eBioMedicine 83 (2022) 104208]

Author

Ozonoff, Al, primary, Schaenman, Joanna, additional, Jayavelu, Naresh Doni, additional, Milliren, Carly E., additional, Calfee, Carolyn S., additional, Cairns, Charles B., additional, Kraft, Monica, additional, Baden, Lindsey R., additional, Shaw, Albert C., additional, Krammer, Florian, additional, van Bakel, Harm, additional, Esserman, Denise A., additional, Liu, Shanshan, additional, Sesma, Ana Fernandez, additional, Simon, Viviana, additional, Hafler, David A., additional, Montgomery, Ruth R., additional, Kleinstein, Steven H., additional, Levy, Ofer, additional, Bime, Chris, additional, Haddad, Elias K., additional, Erle, David J., additional, Pulendran, Bali, additional, Nadeau, Kari C., additional, Davis, Mark M., additional, Hough, Catherine L., additional, Messer, William B., additional, Agudelo Higuita, Nelson I., additional, Metcalf, Jordan P., additional, Atkinson, Mark A., additional, Brakenridge, Scott C., additional, Corry, David, additional, Kheradmand, Farrah, additional, Ehrlich, Lauren I.R., additional, Melamed, Esther, additional, McComsey, Grace A., additional, Sekaly, Rafick, additional, Diray-Arce, Joann, additional, Peters, Bjoern, additional, Augustine, Alison D., additional, Reed, Elaine F., additional, Altman, Matthew C., additional, Becker, Patrice M., additional, and Rouphael, Nadine, additional

Published
2023
Full Text
View/download PDF

48. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma

Author

Aleman, Adolfo, primary, van Kesteren, Morgan, additional, Zajdman, Ariel Kogan, additional, Srivastava, Komal, additional, Cognigni, Christian, additional, Mischka, Jacob, additional, Chen, Lucia Y., additional, Upadhyaya, Bhaskar, additional, Serebryakova, Kseniya, additional, Nardulli, Jessica R., additional, Lyttle, Neko, additional, Kappes, Katerina, additional, Jackson, Hayley, additional, Gleason, Charles R., additional, Oostenink, Annika, additional, Cai, Gianna Y., additional, Van Oekelen, Oliver, additional, van Bakel, Harm, additional, Sordillo, Emilia Mia, additional, Cordon-Cardo, Carlos, additional, Merad, Miriam, additional, Jagannath, Sundar, additional, Wajnberg, Ania, additional, Simon, Viviana, additional, Parekh, Samir, additional, Alshammary, Hala, additional, Andre, Dalles, additional, Banu, Radhika, additional, Beach, Katherine, additional, Bermúdez-González, María Carolina, additional, Chari, Ajai, additional, Chen, Yuexing, additional, Cho, Hearn, additional, Firpo, Adolfo, additional, Gonzalez-Reiche, Ana Silvia, additional, Kim, Eun Hye, additional, Kleiner, Giulio, additional, Krammer, Florian, additional, Mauldin, Jacob, additional, Mendu, Rao, additional, Monahan, Brian, additional, Richard, Shambavi, additional, Richter, Joshua, additional, Rodriguez, Cesar, additional, Rossi, Adrianna, additional, Salimbangon, Ashley, additional, Sanchez, Laryssa, additional, and Verina, Daniel, additional

Published
2023
Full Text
View/download PDF

50. Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave

Author

Hernandez, Matthew M., Gonzalez-Reiche, Ana S., Alshammary, Hala, Fabre, Shelcie, Khan, Zenab, van De Guchte, Adriana, Obla, Ajay, Ellis, Ethan, Sullivan, Mitchell J., Tan, Jessica, Alburquerque, Bremy, Soto, Juan, Wang, Ching-Yi, Sridhar, Shwetha Hara, Wang, Ying-Chih, Smith, Melissa, Sebra, Robert, Paniz-Mondolfi, Alberto E., Gitman, Melissa R., Nowak, Michael D., Cordon-Cardo, Carlos, Luksza, Marta, Krammer, Florian, van Bakel, Harm, Simon, Viviana, and Sordillo, Emilia Mia

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results